

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

9896.129.3.1.1

SERIAL NO.

09/989,033

APPLICANT

Chudzik et al.

FILING

21 November 2001





GROUP

1762


U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---------------------|-----------------|------|------|-------|----------|-------------------------------|
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|---|-----------------|---------|---------|--|--|-------------|----|
| | | | | | | YES | NO |
|  | WO 91/03990 | 4/1991 | WO |  |  | | |
| | WO 91/10424 | 7/1991 | WO | | | | |
| | WO 93/16176 | 8/1993 | WO | | | | |
| | WO 94/11032 | 5/1994 | WO | | | | |
| | WO 94/21309 | 9/1994 | WO | | | | |
| | WO 96/37165 | 11/1996 | WO | | | | |
| | WO 96/39821 | 12/1996 | WO | | | | |
| | WO 97/16544 | 5/1997 | WO | | | | |
| | WO 97/34935 | 9/1997 | WO | | | | |
|  | WO 99/08717 | 2/1999 | WO | | | | |


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|---|---|
|  | Eliasz R, Wallach D, Kost J, Long-term protection against the effects of tumor necrosis factor by controlled delivery of the soluble p55 TNF receptor, Cytokine, 1996, Jun; 8(6): 482-7. |
| | Flemmig TF, Weinacht S, Rudiger S, Rumetsch M, Jung A, Klaiber B, Adjunctive controlled topical application of tetracycline HCl in the treatment of localized persistent or recurrent periodontitis. Effects on clinical parameters and elastase-alpha1-proteinase inhibitor in gingival crevicular fluid, J Chin Periodontol 1996 OCT; 23 (10):914-21. |
| | Folkman J, How the field of controlled-release technology began, and its central role in the development of angiogenesis research, Biomaterials, 1990, Nov; 11 (9): 615-8. |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.

9896.129.3.1.1

SERIAL NO.

09/989,033

APPLICANT

Chudzik et al.

FILING

21 November 2001

GROUP

1762

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---------------------|-----------------|------|------|-------|----------|-------------------------------|
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|--|-----------------|---------|---------|-------|----------|-------------|----|
| | | | | | | YES | NO |
| | WO 99/16907 | 4/1999 | WO | | | | |
| | WO 99/43688 | 9/1999 | WO | | | | |
| | WO 99/47129 | 9/1999 | WO | | | | |
| | WO 99/47176 | 9/1999 | WO | | | | |
| | WO 99/64086 | 12/1999 | WO | | | | |
| | WO 00/12163 | 3/2000 | WO | | | | |
| | WO 00/40593 | 7/2000 | WO | | | | |
| | WO 00/55396 | 9/2000 | WO | | | | |
| | WO 01/21326 | 3/2001 | WO | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|--|---|
| | Friling R, Yassar Y, Levy R, Kost J, Schwartz B, Mikhailowsky R, Lamprecht SA, A role of transforming growth factor-beta 1 in the control of corneal neovascularization, In Vivo 10, 59-64 (1996). |
| | Goodson JM, Hogan PE, Dunham SL, Clinical responses following periodontal treatment by local drug delivery, J Periodontal 1985 Nov; 56 (11 Suppl): 81-7. |
| | Huland E, Falk B, Hubner D, Huland H, In vivo system to detect long-term continuous release of bioactive interleukin-2 by immunopharmacological depot preparations in nude mice with human tumors, Int. J. Cancer, 1995, 62, 605-9. |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

9896.129.3.1.1

SERIAL NO.

09/989,033

APPLICANT

Chudzik et al.

FILING

21 November 2001

GROUP

1762

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---------------------|-----------------|------|------|-------|----------|-------------------------------|
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|--|-----------------|---------|---------|-------|----------|-------------|----|
| | | | | | | YES | NO |
| | WO 01/36008 | 5/2001 | WO | | | | |
| | WO 01/44174 | 6/2001 | WO | | | | |
| | WO 01/66161 | 9/2001 | WO | | | | |
| | WO 01/87342 | 11/2001 | WO | | | | |
| | WO 01/87372 | 11/2001 | WO | | | | |
| | WO 01/87373 | 11/2001 | WO | | | | |
| | WO 01/87374 | 11/2001 | WO | | | | |
| | WO 01/87375 | 11/2001 | WO | | | | |
| | WO 01/87376 | 11/2001 | WO | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|--|---|
| | Lees VC, Fan TP, West DC, Angiogenesis in a delayed revascularization model is accelerated by angiogenic oligosaccharides of hyaluronan, Lab Invest, 1995, 73, 259-66. |
| | Lesser GJ, Grossman SA, Leong KW, et al., In vitro and in vivo studies of subcutaneous hydromorphone implants designed for the treatment of cancer pain, Pain, 1996, May-Jun; 65 (2-3): 265-72. |
| | Lopez JJ, Edelman ER, Stamler A, et al., Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia, Am J Physiol 1998 Mar; 274 (3 Pt 2): H930. |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | | | | | | |
|---|--|--|--|---|--|---------------------------------|--|
| INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) | | | | ATTY. DOCKET NO. 9896.129.3.1.1 | | SERIAL NO. 09/989,033 | |
| | | | | APPLICANT Chudzik et al. | | | |
| | | | | FILING 21 November 2001 | | GROUP 1762 | |

OIPE
 DEC 13 2004
 PATENT & TRADEMARK OFFICE

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|-----------------|------|------|-------|----------|----------------------------|--|
| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|-----------------|---------|---------|-------|----------|-------------|----|
| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | YES | NO |
| | WO 02/26139 | 4/2002 | WO | | | | |
| | WO 02/26271 | 4/2002 | WO | | | | |
| | WO 02/26281 | 4/2002 | WO | | | | |
| | WO 03/022323 | 3/2003 | WO | | | | |
| | WO 03/064015 | 8/2003 | WO | | | | |
| | WO 04/000267 | 12/2003 | WO | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | |
|--|--|
| | Ozaki H, Hayashi H, Vinorel SA, Moromizato Y, Campochiaro PA, Oshima K, Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates, Exp Eye Res, 1997, 64, 505-17. |
| | Sellke FW, Li J, Stamler A, Lopez JJ, Thomas KA, Simons M, Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia, Surgery 1996 Aug; 120 (2): 182-8. |
| | Suzuki, T. et al. Stent-based delivery of sirolimus release. Circulation 2001; 104: 1188-1193. |
| EXAMINER | DATE CONSIDERED |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

9896.129.3.1.1

SERIAL NO.

09/989,033

APPLICANT

Chudzik et al.

FILING

21 November 2001

GROUP

1762

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---------------------|-----------------|------|------|-------|----------|-------------------------------|
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |


FOREIGN PATENT DOCUMENTS

| | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|--|-----------------|------|---------|-------|----------|-------------|----|
| | | | | | | YES | NO |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)






| | |
|----------|---|
| | Jafari, F, et al Point Counterpoint: Drug Eluting Stent Euphoria NOT A PUBLICATION |
| | Morice et al, A Randomized Comparison of a Sirolimus-Eluting Stent, N Engl J Med, 2002 June; 346, 1773-1780 |
| | Raman et al, Coated Stents: Local Pharmacology, Semin Intervent Cardiol 1998: 3: 133-137 |
| EXAMINER | DATE CONSIDERED |

EXAMINER: initial reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


| | | | | | | | |
|--|--|--|--|---|--|---------------------------------|--|
|  <p>INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p> | | | | ATTY. DOCKET NO. 9896.129.3.1.1 | | SERIAL NO. 09/989,033 | |
| | | | | APPLICANT Chudzik et al. | | | |
| | | | | FILING 21 November 2001 | | GROUP 1762 | |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|--|-----------------|------|------|-------|----------|-------------------------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|--|-----------------|------|---------|-------|----------|-------------|----|
| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | | YES | NO |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | |
|--|--|
|  | Whelan et al, Mechanisms of Drug Loading and Release Kinetics, Semin Intervent Cardiol 1998; 3: 127-131 |
|  | Klugherz et al, Twenty-eight-day Efficacy and Pharmacokinetics, Coronary Artery Disease 2002 13 (3) |
|  | Regar et al, Stent Development and Local Drug Delivery, British Med Bulletin 2001; 59: 227-48 |
| EXAMINER  | DATE CONSIDERED  |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.

9896.129.3.1.1

SERIAL NO.

09/989,033

APPLICANT

Chudzik et al.

FILING

21 November 2001

GROUP

1762

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---------------------|-----------------|------|------|-------|----------|-------------------------------|
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|--|-----------------|------|---------|-------|----------|-------------|----|
| | | | | | | YES | NO |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Serruys et al., Rapamycin Eluting Stent: the Onset of a New Era in Interventional Cardiology, Heart 2002 (87) 305-307

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.